Squamous cell carcinoma is one of the most common and aggressive types of cancer in the head and neck region. It is the fifth ...

Prognosis is extremely poor for patients with head and neck squamous cell carcinoma (HNSCC), which accounts for around 90% of all head and neck cancer. Especially in the more aggressive subtype of ...

Please provide your email address to receive an email when new articles are posted on . Patients who received nivolumab had longer DFS than those who received standard care. OS will be evaluated after ...

Esophageal cancer occurring in patients with head and neck squamous cell carcinoma (HNSCC) represents a critical clinical challenge, as these secondary tumours notably worsen patient prognosis. Owing ...

Adding neoadjuvant and adjuvant pembrolizumab to the standard of care significantly improved event-free survival in patients with previously untreated, locally advanced head and neck squamous cell ...

Compared with standard concurrent chemoradiation, neoadjuvant chemotherapy followed by transoral robotic surgery (NECTORS) and neck dissection led to superior distant metastasis-free and overall ...

(ORR) and 92% disease control rate (DCR) observed with MICVO as monotherapy in 2L+ R/M HNSCC at 5.4 mg/kg 71% confirmed ORR ...

Sense of smell in patients with head and neck cancer began to deteriorate at a radiation dose of 22 Gy and increased in a ...